FINWIRES · TerminalLIVE
FINWIRES

ASX:BXN

3 stories mentioning ASX:BXNUpdated 41d ago

Every FINWIRES story that references ASX:BXN, newest first.

Asia

Bioxyne Unit Signs AU$50 Million Medicinal Cannabis Supply Deal With ADREXpharma

Bioxyne, (ASX:BXN) through its subsidiary Breathe Life Sciences, has secured a two-year AU$50 million agreement with German pharmaceutical firm ADREXpharma to supply Good Manufacturing Practice (GMP)-produced medicinal cannabis products into Germany, according to a Tuesday filing with the Australian bourse.The agreement includes a minimum purchase commitment of AU$25 million within the first 12 months, offering near-term revenue visibility, and will automatically renew for another 12-month term, per the filing.The agreement extends an existing partnership, strengthening the company's position in Germany and supporting its expansion of GMP-certified production and regulated pharmaceutical supply across Europe, the filing added.

ASX:BXN
Asia

Bioxyne Unit Expands Supply Deal With Pharmaceutical Distributor; Shares Up 4%

Bioxyne's (ASX:BXN) Breathe Life Sciences subsidiary executed an expanded supply agreement with pharmaceutical distributor Remidose LATAM to include three Dr Watson cannabis flower stock-keeping unit (SKUs) to Costa Rica, according to a Monday filing with the Australian bourse.Initial shipment is scheduled before June 30, with an invoice value exceeding AU$500,000, the filing said.Shares rose 4% in morning trade on Monday.

ASX:BXN
Asia

Bioxyne Reports 137% Jump in Fiscal Q3 Revenue; Shares Fall 3%

Bioxyne (ASX:BXN) reported a record revenue of AU$21.3 million for the fiscal third quarter, up 137% from a year earlier, driven by increased demand for its GMP manufactured medicinal cannabis, MDMA, and psilocybin products, according to a Tuesday Australian bourse filing.Cash receipts came in at AU$20.9 million during the three months ended March 31, compared with AU$8.5 million in the same period in the previous year.The company expects its fiscal 2026 revenue to be in the range of AU$65 million to AU$75 million and adjusted earnings before interest, taxes, depreciation, and amortization in the range of AU$16.5 million to AU$19 million.The company's shares fell about 3% in recent Tuesday trade.

ASX:BXN

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:BXN in your portfolio
WheelAI
WheelAI
Analyze ASX:BXN options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:BXN